ArticlePloS one2013
Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Immunity as a predictor of anti-malarial treatment failure: a systematic review.Malaria journal · 2017Pooled it
- Differential Patterns of IgG Subclass Responses toFrontiers in immunology · 2019Trial
- The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial.Malaria journal · 2015Trial
- Development of flow cytometry bead-based opsonophagocytic assays to dissect cell-mediated functional antibody responses to malaria vaccines.Malaria journal · 2026Article
- Distribution of Plasmodium falciparum apical membrane antigen-1 cluster one loop haplotypes and their association with malaria symptoms in Bandiagara, Mali.BMC infectious diseases · 2026Article
- Vaccine-induced mouse antibodies targeting Plasmodium falciparum PfVFT antigen inhibit blood stages through multiple mechanisms.NPJ vaccines · 2026Article
- Relationship between antibody avidity, Fc-mediated functional activity and longevity of malaria vaccine responses in clinical trials.Frontiers in immunology · 2026Article
- Systems approach identifies monocyte imbalance in symptomatic and asymptomatic P. vivax malaria.Molecular systems biology · 2025Article
- Full-length merozoite surface protein 1 formulated with GLA-SE adjuvant in malaria pre-exposed adults: a randomised, controlled, double-blind, parallel-group, single-centre Phase Ib trial.EClinicalMedicine · 2025Article
- Interleukin-10 limits immune-mediated pathology in chronic subclinical plasmodial infection.PLoS neglected tropical diseases · 2025Article
- FcγR binding differentially contributes to protection by two human monoclonal antibodies targetingScience translational medicine · 2025Article
- Article
- Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.Life science alliance · 2024Article
- Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.Immunity · 2024Article
- How to Accelerate Early Stage of Malaria Vaccine Development by Optimizing Functional Assays.Vaccines · 2024Review
- Article
- Antibody-Dependent Respiratory Burst againstVaccines · 2024Article
- Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine.NPJ vaccines · 2023Article
- Human blood neutrophils generate ROS through FcγR-signaling to mediate protection against febrile P. falciparum malaria.Communications biology · 2023Article
- Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
Naturally acquired humoral immunity to the malarial parasite Plasmodium falciparum can protect against disease, although the precise mechanisms remain unclear. Although antibody levels can be measured by ELISA, few studies have investigated functional antibody assays in relation to clinical outcomes. In this study we applied a recently developed functional assay of antibody-mediated opsonisation of merozoites, to plasma samples from a longitudinal cohort study conducted in a malaria endemic region of Papua New Guinea (PNG). Phagocytic activity was quantified by flow cytometry using a standardized and high-throughput protocol, and was subsequently evaluated for association with protection from clinical malaria and high-density parasitemia. Opsonising antibody responses were found to: i) increase with age, ii) be enhanced by concurrent infection, and iii) correlate with protection from clinical episodes and high-density parasitemia. Stronger protective associations were observed in individuals with no detectable parasitemia at baseline. This study presents the first evidence for merozoite phagocytosis as a correlate of acquired immunity and clinical protection against P. falciparum malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.